← Back to Search

Other

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 1, 2, 4, 6, 8, 10 and 12

Summary

This trial tests a new skin ointment called PF-07038124 for people with Atopic Dermatitis or plaque psoriasis. Participants will use the ointment daily for a few months to see if it is safe and effective. The study will compare different doses of the ointment.

Eligible Conditions
  • Atopic Dermatitis
  • Plaque Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 1, 2, 4, 6, 8, 10 and 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 1, 2, 4, 6, 8, 10 and 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants With Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of More Than or Equal to (>=) 2 Points at Week 12: Participants With Atopic Dermatitis (AD) Only
Percentage of Participants With Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Week 12: Participants With Plaque Psoriasis Only
Secondary study objectives
Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only
Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG): Participants With Atopic Dermatitis and Plaque Psoriasis
+14 more

Trial Design

7Treatment groups
Experimental Treatment
Placebo Group
Group I: Plaque Psoriasis PF-07038124 0.06% ointmentExperimental Treatment1 Intervention
Plaque Psoriasis
Group II: Plaque Psoriasis PF-07038124 0.03% ointmentExperimental Treatment1 Intervention
Plaque Psoriasis
Group III: Plaque Psoriasis PF-07038124 0.01% ointmentExperimental Treatment1 Intervention
Plaque Psoriasis
Group IV: Atopic Dermatitis PF-07038124 0.03% ointmentExperimental Treatment1 Intervention
Atopic Dermatitis
Group V: Atopic Dermatitis PF-07038124 0.01% ointmentExperimental Treatment1 Intervention
Atopic Dermatitis
Group VI: Atopic Dermatitis Vehicle ointmentPlacebo Group1 Intervention
Atopic Dermatitis
Group VII: Plaque Psoriasis Vehicle ointmentPlacebo Group1 Intervention
Plaque Psoriasis
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07038124 ointment 0.01%
2022
Completed Phase 2
~270
PF-07038124 ointment 0.06%
2022
Completed Phase 2
~270
PF-07038124 ointment 0.03%
2022
Completed Phase 2
~270

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,675 Previous Clinical Trials
28,716,918 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,556 Previous Clinical Trials
25,757,774 Total Patients Enrolled
~83 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top